Form 8-K - Current report:
SEC Accession No. 0001029142-25-000031
Filing Date
2025-02-14
Accepted
2025-02-14 16:28:20
Documents
13
Period of Report
2025-02-10
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K dvax-20250210.htm   iXBRL 8-K 27672
  Complete submission text file 0001029142-25-000031.txt   155660

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dvax-20250210.xsd EX-101.SCH 1854
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dvax-20250210_lab.xml EX-101.LAB 22804
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dvax-20250210_pre.xml EX-101.PRE 13115
16 EXTRACTED XBRL INSTANCE DOCUMENT dvax-20250210_htm.xml XML 2917
Mailing Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 720 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 25629512
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)